Efficacy of inhaled steroids in undiagnosed subjects at high risk for COPD: Results of the detection, intervention, and monitoring of COPD and asthma program

Chest

Volumn 126, Issue 6, 2004, Pages 1815-1824

  Albers, Mieke ^a   Schermer, Tjard ^a   Van Den Boom, Guido ^a,c   Akkermans, Reinier ^a   Van Schayck, Constant ^b   Van Herwaarden, Cees ^a   Van Weel, Chris ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c Novartis Pharmaceuticals Corporation   (Netherlands)

Author keywords

COPD; Early treatment; Inhaled corticosteroid; Lung function decline

Indexed keywords

BRONCHODILATING AGENT; FLUTICASONE PROPIONATE; PLACEBO; STEROID;

ADULT; ARTICLE; ASTHMA; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HEALTH CARE UTILIZATION; HEALTH STATUS; HIGH RISK POPULATION; HUMAN; LUNG FUNCTION; MALE; OPEN STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 10444228113     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.126.6.1815     Document Type: Article

References (35)

1. Murray CJL, Lopez AD. Alternative visions of the future: projecting mortality and disability, 1990-2020. In: Murray CJL, Lopez AD, eds. The global burden of disease. Cambridge, MA: The Harvard School of Public Health, on behalf of the World Health Organization and the World Bank, 1996; 361-395
2. Tirimanna PR, Van Schayck CP, Den Otter JJ, et al. Prevalence of asthma and COPD in general practice in 1992: has it changed since 1977? Br J Gen Pract 1996; 46:277-281
3. Stang P, Lydick E, Silberman C, et al. The prevalence of COPD: using smoking rates to estimate disease frequency in the general population, Chest 2000; 117(suppl):354s-359s
4. Van den Boom G, Van Schayck CP, Rutten-van Molken MP, et al. Active detection of chronic obstructive pulmonary disease and asthma in the general population: results and economic consequences of the DIMCA program. Am J Respir Crit Care Med 1998; 158:1730-1738
5. Dompeling E, Van schayk CP, Van Grunsven PM, et al. Slowing the deterioration of asthma and COPD during bronchodilator therapy by adding inhaled corticosteroids: a four-year prospective study. Ann Intern Med 1993; 118:770-778
6. Overbeek SE, Kerstjens HA, Bogaard JM, et al. Is delayed introduction of corticosteroids harmful in patients with obstructive airways disease (asthma and COPD)? The Dutch Chronic Nonspecific Lung Disease Study Group. Chest 1996; 110:35-41
7. Kerstjens HA, Brand PL, Hughes MD, et al. A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease: Dutch Chronic Non-Specific Lung Disease Study Group. N Engl J Med 1992; 327:1413-1419
8. Van Grunsven PM, Van Schayck CP, Molema J, et al. Effect of inhaled corticosteroids on bronchial responsiveness in patients with "corticosteroid naive" mild asthma: a meta analysis. Thorax 1999; 54:316-322
9. Pauwels R. Inhaled glucocorticosteroids and chronic obstructive pulmonary disease: how full is the glass? Am J Respir Crit Care Med 2002; 165:1579-1580
10. Fabbri LM, Kurd SS, the GOLD Scientific Committee. Global Strategy for the Diagnosis, Management and Prevention of COPD: 2003 update. Eur Respir J 2003; 22:1-2
11. Fletcher C, Peto R. The natural history of chronic airflow obstruction. BMJ 1977; 1:1645-1648
12. Burrows B, Bloom JW, Traver GA, et al. The course and prognosis of different forms of chronic airways obstruction in a sample of the general population. N Engl J Med 1987; 317:1309-1314
13. Peat JK, Woolcock AJ, Cullen K. Rate of decline of lung function in subjects with asthma. Eur J Respir Dis 1987; 70:171-179
14. Burge PS, Calverley PMA, Jones PW, et al. on behalf of the ISOLDE study investigators: randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease; the ISOLDE trial. BMJ 2000; 320:1297-1303
15. Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking: European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999; 340:1948-1953
16. Van den Boom G, Rutten-Van Mölken PMH, Molema J, et al. The cost-effectiveness of early treatment with fluticasone propionate 250 mug twice a day in subjects with obstructive airway disease. Am J Respir Crit Care Med 2001; 164:2057-2066
17. Sutherland ER, Allmers H, Ayas NT, et al. Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax 2003; 58:937-941
18. Spencer S, Calverley PM, Burge PS, et al. Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163:122-128
19. Paggiaro PL, Dahle R, Bakran I, et al. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease: International COPD Study Group. Lancet 1998; 351:773-780
20. National Institutes of Health. Highlights of the expert panel report 2: guidelines for the diagnosis and management of asthma. Bethesda, MD: National Institutes of Health, 1997; NIH publication 97-4051A
21. Lundbäck B, Gulsvik A, Albers M, et al. Epidemiological aspects and early detection of chronic obstructive airway diseases in the elderly. Eur Respir J 2003; 21(suppl 40):3s-9s
22. Van Grunsven PM, Van Schayck CP, Van Deuveren M. Compliance during long-term treatment with fluticasone propionate in subjects with early signs of asthma or chronic obstructive pulmonary disease (COPD): results of the Detection, Intervention, and Monitoring Program of COPD and Asthma (DIMCA) Study. J Asthma 2000; 37:225-234
23. American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 1995; 52:1107-1136
24. Dompeling E, Van Schayck CP, Folgering H, et al. Accuracy, precision and linearity of the portable flow-volume meter Microspiro HI-298. Eur Respir J 1991; 4:612-615
25. Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows: Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal; Official Statement of the European Respiratory Society. Eur Respir J 1993; 16(suppl):5-40
26. Cockcroft DW, Killian DN, Mellon JJ, et al. Bronchial reactivity to inhaled histamine: a method and clinical survey. Clin Allergy 1977; 7:235-243
27. Rutten-Van Molken MP, Custers F, Van Doorslaer EK, et al. Comparison of performance of four instruments in evaluating the effects of salmeterol on asthma quality of life. Eur Respir J 1995; 8:888-898
28. Torrance GW, Feeny DH, Furlong WJ, et al. Multiattribute utility function for a comprehensive health status classification system: Health Utilities Index Mark 2. Med Care 1996; 34:702-722
29. Guyatt GH, Berman LB, Townsend M, et al. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987; 42:773-778
30. Juniper EF, Guyatt GH, Willan A, et al. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol 1994; 47:81-87
31. D. M. Hawkins. Point estimation of the parameters of piecewise regression models. Appl Stat 1976; 25:51-57
32. Van Grunsven PM, Van Schayck CP, Derenne JP, et al. Long-term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta analysis. Thorax 1999; 54:7-14
33. Vestbo J, Sorensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353:1819-1823
34. Wise MD, Connet J, Weinmann G, et al. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343:1902-1909
35. 1. Am J Respir Crit Care Med 1995; 151:377-1382